Sponsors
Capping U.S. prescription drug list prices at an international average could lower costs for patients and government programs, but risks manufacturer responses that raise net prices, limit supply, and slow innovation while imposing enforcement costs.
Patients — including Medicare and Medicaid beneficiaries — would pay lower prescription drug retail list prices because U.S. prices would be capped at the six-country average, which would also likely reduce federal and state program spending on drugs.
Taxpayers and policymakers would gain greater transparency into international and U.S. drug list prices through annual manufacturer reporting to HHS.
Drug manufacturers may respond to the cap by raising list prices elsewhere, shifting costs onto insurers or employers, reducing supply, or withdrawing products from the U.S. market, which could lead to higher net prices or reduced access for patients and higher costs for small businesses.
Some innovative drug makers may cut R&D investments or delay U.S. launches if returns are constrained, potentially slowing the arrival of new therapies and harming long-term patient health outcomes.
HHS will need substantial administrative capacity to verify foreign price data and enforce penalties, creating additional implementation costs, complexity, and possible delays in the policy's effect.
Based on analysis of 2 sections of legislative text.
Caps U.S. retail list prices for drugs and biologics at the annual average list price across six foreign countries, requires annual manufacturer price reports, and imposes penalties for excesses.
Introduced May 13, 2025 by Jefferson Van Drew · Last progress May 13, 2025
Caps the U.S. retail list price of any FDA-approved drug or biologic so it cannot exceed the annual average list price of that product across six foreign countries (Canada, France, Germany, Italy, Japan, and the UK). Drug and biologic manufacturers must report U.S. and each foreign list price to HHS every year. If a manufacturer’s U.S. list price exceeds that six-country average, the manufacturer faces civil monetary penalties equal to 10 times the per-unit difference, assessed for each unit sold. The HHS Secretary must publish guidance and issue regulations to carry out the requirements and pricing calculations.